FDAsafety guidance72% confidence
Ongoing | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (colorectal cancer) as existing therapies for MSS colorectal cancer.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Supporting Context
- Therapeutic area
- Oncology · Colorectal Cancer
- Sub-indication
- Colorectal Cancer
Related signal: Chemoimmunotherapy Shows Promise in MSS Colorectal Cancer: Pooled Analysis Insights